Agilent Technologies, Inc. $A Stock: Generate Investment Management Ltd Boosts Stake

Generate Investment Management Ltd boosted its stake in Agilent Technologies, Inc. (NYSE:A) by 10.8% during the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 89,766 shares of the medical research company’s stock after buying an additional 8,720 shares during the period. Generate Investment Management Ltd’s holdings in Agilent Technologies were worth $15,468,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of the stock. First Citizens Bank & Trust Co. bought a new position in shares of Agilent Technologies during the third quarter valued at $1,080,000. ProCore Advisors LLC grew its holdings in shares of Agilent Technologies by 4.8% in the 3rd quarter. ProCore Advisors LLC now owns 2,290 shares of the medical research company’s stock worth $395,000 after purchasing an additional 104 shares during the last quarter. B. Riley Wealth Advisors Inc. grew its holdings in shares of Agilent Technologies by 64.5% in the 3rd quarter. B. Riley Wealth Advisors Inc. now owns 2,874 shares of the medical research company’s stock worth $495,000 after purchasing an additional 1,127 shares during the last quarter. Krilogy Financial LLC grew its holdings in shares of Agilent Technologies by 4.7% in the 3rd quarter. Krilogy Financial LLC now owns 4,933 shares of the medical research company’s stock worth $845,000 after purchasing an additional 221 shares during the last quarter. Finally, Fragasso Financial Advisors Inc increased its position in shares of Agilent Technologies by 10.3% during the 3rd quarter. Fragasso Financial Advisors Inc now owns 2,116 shares of the medical research company’s stock worth $361,000 after purchasing an additional 198 shares in the last quarter.

Analyst Upgrades and Downgrades

A has been the subject of several analyst reports. UBS Group began coverage on shares of Agilent Technologies in a report on Wednesday, September 9th. They set a “neutral” rating and a $165.00 price target for the company. Sanford C. Bernstein boosted their price target on shares of Agilent Technologies from $155.00 to $180.00 and gave the company an “outperform” rating in a research report on Thursday, August 27th. Stifel Nicolaus upped their price objective on shares of Agilent Technologies from $170.00 to $180.00 and gave the stock a “buy” rating in a research note on Thursday, August 27th. Jefferies Financial Group initiated coverage on shares of Agilent Technologies in a report on Thursday, July 9th. They set a “hold” rating and a $135.00 price objective for the company. Finally, Morgan Stanley raised their price objective on shares of Agilent Technologies from $175.00 to $190.00 and gave the stock an “overweight” rating in a report on Tuesday. Fifteen equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $173.65.

Agilent Technologies Price Performance

Agilent Technologies stock traded up $0.91 on Wednesday, reaching $172.51. The company’s stock had a trading volume of 659,733 shares, compared to its average volume of 2,258,416. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.56 and a current ratio of 2.05. The company has a market cap of $48.64 billion, a price-to-earnings ratio of 33.96, a PEG ratio of 2.61 and a beta of 1.21. The business’s fifty day moving average price is $157.13 and its 200 day moving average price is $136.41. Agilent Technologies, Inc. has a twelve month low of $108.35 and a twelve month high of $177.05.

Agilent Technologies (NYSE:A) last announced its earnings results on Wednesday, August 26th. The medical research company reported $1.62 earnings per share for the quarter, beating analysts’ consensus estimates of $1.49 by $0.13. Agilent Technologies had a return on equity of 24.45% and a net margin of 19.53%. The company had revenue of $1.88 billion during the quarter, compared to analyst estimates of $1.84 billion. During the same period last year, the company posted $1.37 earnings per share. The firm’s quarterly revenue was up 8.1% compared to the same quarter last year. Agilent Technologies has set its Q4 2026 guidance at 1.710-1.740 EPS and its FY 2026 guidance at 6.180-6.210 EPS. Equities analysts expect that Agilent Technologies, Inc. will post 6.20 earnings per share for the current fiscal year.

Agilent Technologies Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 28th. Shareholders of record on Tuesday, October 6th will be given a $0.2550 dividend. This represents a $1.02 annualized dividend and a yield of 0.6%. The ex-dividend date is Tuesday, October 6th. Agilent Technologies’s dividend payout ratio (DPR) is presently 20.08%.

More Agilent Technologies News

Here are the key news stories impacting Agilent Technologies this week:

• Positive Sentiment: Proscia acquisition expands AI strategy: Agilent agreed to acquire digital pathology software company Proscia for $240 million upfront, with the transaction potentially reaching $270 million including milestone payments. The deal is intended to strengthen Agilent’s AI-enabled digital pathology and scientific intelligence capabilities, adding a strategic growth platform in clinical and research markets. Agilent to Acquire Proscia, Advancing AI-Enabled Digital Pathology and Scientific Intelligence
• Positive Sentiment: Analysts raised price targets: Morgan Stanley lifted its target from $175 to $190 and maintained an overweight rating, while TD Cowen raised its target from $180 to $196 and upgraded or maintained a buy rating. The revisions suggest analysts see additional upside following Agilent’s recent earnings outperformance and growth initiatives. TD Cowen Adjusts Price Target on Agilent Technologies to $196 From $180
• Positive Sentiment: Metabolomics market provides a growth tailwind: A new industry report projects a 17.3% compound annual growth rate through 2030, citing rising adoption of AI diagnostics and continued activity from Agilent, Thermo Fisher, Bruker and Metabolon. The outlook supports demand for Agilent’s analytical and life-science technologies. Global Metabolomics Market Report 2026
• Neutral Sentiment: China expansion: Agilent plans to expand its capabilities in China, potentially improving local customer support and strengthening its position in a major life-science market. However, China-related demand, trade conditions and regulatory risks remain considerations for investors. Agilent to expand capabilities in China

Insiders Place Their Bets

In other Agilent Technologies news, Director Mikael Dolsten sold 634 shares of the business’s stock in a transaction dated Friday, September 4th. The shares were sold at an average price of $151.38, for a total value of $95,974.92. Following the completion of the transaction, the director directly owned 4,924 shares of the company’s stock, valued at approximately $745,395.12. The trade was a 11.41% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Agilent Technologies Company Profile

Agilent Technologies, Inc is an analytical measurement and laboratory technology company serving the life sciences, diagnostics, pharmaceutical, chemical, environmental, food, energy and academic research markets. Its solutions help laboratories analyze the composition, quality and performance of materials, biological samples and other substances.

The company’s products and services include liquid and gas chromatography systems, mass spectrometry instruments, spectroscopy equipment, laboratory automation tools, software, consumables and supplies.